Dublin, Ireland – December 9, 2025 – ProVerum Limited announced that the U.S. Food and Drug Administration has granted approval for the ProVee® System, marking the debut of a new generation of prostatic urethral stents designed to treat benign prostatic hyperplasia (BPH) without cutting, burning, or piercing tissue. This regulatory milestone introduces a minimally invasive solution that can be deployed in an outpatient setting and has demonstrated strong clinical performance, durable symptom relief, and an excellent safety profile in a pivotal randomized clinical trial.
Science Significance
The ProVee System represents a notable advancement in urological device science, leveraging a novel mechanical approach to gently open the obstructed prostatic urethra while preserving surrounding tissue and sexual function. Unlike thermal ablation or resection-based BPH interventions, the ProVee implant delivers relief using controlled anatomical expansion, reducing the biological stress associated with conventional procedures. Supported by the ProVIDE randomized, double-blind, sham-controlled study, the device achieved all primary and secondary endpoints, confirming significant improvements in urinary flow, symptom reduction, and functional outcomes through 12 months. The lack of device-related serious adverse events and the absence of post-procedure catheterization underscore the biomechanical safety and anatomical precision of this next-generation device.
Regulatory Significance
FDA approval of ProVee holds considerable regulatory weight, as it validates a new class of prostatic urethral stent technology underpinned by rigorous safety and efficacy data. The ProVIDE study’s robust clinical design aligns closely with modern regulatory expectations for implantable urological devices, including sham control, long-term follow-up, and preservation of patient-reported outcomes such as sexual function. The approval reflects the Agency’s support for minimally invasive alternatives that expand therapeutic options while reducing peri-procedural risk. Moreover, this clearance establishes regulatory precedent for future tissue-sparing urological implants and emphasizes the FDA’s commitment to patient-centric device innovation within a commonly treated chronic condition.
Business Significance
Advertisement
For ProVerum, the FDA approval of ProVee marks its transition from development-stage innovator to commercial-stage medical device company. The U.S. market — home to more than 12 million men actively managed for BPH — represents a substantial opportunity for adoption of a device that is simpler, safer, and faster to perform than many current interventions. The ProVee System enables operational efficiencies for urologists, allowing procedures to be completed rapidly and without complex energy-based systems, which can benefit ambulatory surgical centers and office-based practices. FDA approval strengthens ProVerum’s competitive position in the rapidly expanding field of minimally invasive BPH solutions and may catalyze investor interest, health-system partnerships, and accelerated market penetration as clinicians seek alternatives to traditional surgical approaches.
Patients’ Significance
For patients, the ramp-up at Forj Medical’s new facility promises faster availability of advanced medical devices, potentially at lower cost. Devices manufactured from this plant — including biosensors, minimally invasive sensor-driven implants, drug-delivery devices and cardiovascular systems — may reach markets more quickly, enabling earlier access to innovative treatments and therapies. Improved manufacturing quality, reliability and scalability also reduce risk of device failure or supply shortages, which directly benefits patient safety and continuity of care.
Policy Significance
For patients, the introduction of the ProVee System means greater access to fast, safe, and minimally invasive relief from BPH symptoms, including urgency, weak flow, nocturia, and incomplete emptying — issues that significantly impair daily life for millions of aging men. The clinical data highlight rapid recovery, no requirement for catheterization, and preserved sexual function, addressing key concerns that often deter patients from pursuing interventional procedures. By avoiding thermal damage or tissue removal, ProVee offers an appealing option for men seeking meaningful symptom improvement without compromising quality of life. Its outpatient applicability and simplified procedural workflow may also increase treatment accessibility in underserved regions and smaller clinical practices.
As BPH represents one of the most common urological conditions globally, FDA approval of ProVee aligns with public-health priorities to broaden access to safe, effective, and cost-conscious treatment pathways. Policymakers and payers increasingly value minimally invasive technologies that reduce procedural complexity, shorten recovery times, and minimize hospital resource utilization. The ProVee System reflects a shift toward scaling outpatient-based solutions, which may support healthcare cost containment, reduce operating-room burden, and improve care efficiency. Regulatory recognition of new stent-based BPH therapies also signals potential updates in clinical guidelines and reimbursement frameworks that encourage adoption of less invasive, evidence-backed urological innovations.
Source: ProVerum Limited press release
